Volume 73, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


To support the global program to eliminate lymphatic filariasis (LF), well-monitored demonstration projects are important for defining the relationship between coverage and reductions in microfilaremia. We are using mass treatment with diethylcarbamazine (DEC) and albendazole in an effort to eliminate LF from Leogane, Haiti. microfilaremia prevalence at baseline ranged from 0.8% to 15.9% in four sentinel sites. After three rounds of DEC-albendazole mass drug administration (MDA), both microfilaremia prevalence and intensity decreased dramatically. Mild and moderate adverse reactions after treatment were common, especially after the first MDA, but decreased after subsequent MDAs. Drug coverage for the first year was estimated to be 72%, but concerns about adverse reactions appeared to decrease drug coverage in the second MDA. As a result of community education efforts that focused on providing a greater understanding of adverse reactions, coverage increased dramatically for the third round. Program efficiency increased substantially; the costs per person treated for three rounds of MDA were $2.23, $1.96, and $1.30 per person, respectively. The Leogane experience highlights the importance of adapting community education and mobilization campaigns to achieve and maintain good coverage.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Molyneux DH, Zagaria N, 2002. Lymphatic filariasis elimination: progress in global programme development. Ann Trop Med Parasitol 96 : S15–S40. [Google Scholar]
  2. Ottesen EA, Duke BOL, Karam M, Behbehani K, 1997. Strategies and tools for the control/elimination of lymphatic filariasis. Bull World Health Organ 75 : 491–503. [Google Scholar]
  3. Cao WC, Xu JF, Ren ZX, 1994. Epidemiological surveillance of filariasis after its control in Shandong Province, China. Southeast Asian J Trop Med Public Health 25 : 714–718. [Google Scholar]
  4. Webber RH, 1979. Eradication of Wuchereria bancrofti infection through vector control. Trans R Soc Trop Med Hyg 73 : 722–724. [Google Scholar]
  5. Rawlins SC, Siung-Chang A, Baboolal S, Chadee DD, 2004. Evidence for the interruption of transmission of lymphatic filariasis among schoolchildren in Trinidad and Tobago. Trans R Soc Trop Med Hyg 98 : 473–477. [Google Scholar]
  6. Chernin E, 1987. The disappearance of Bancroftian filariasis from Charleston, South Carolina. Am J Trop Med Hyg 37 : 111–114. [Google Scholar]
  7. Weil GJ, Lammie PJ, Weiss N, 1997. The ICT filariasis test: A rapid format antigen test for diagnosis of Bancroftian filariasis. Parasitol Today 13 : 401–404. [Google Scholar]
  8. Brown KR, Ricci FM, Ottesen EA, 2000. Ivermectin: effectiveness in lymphatic filariasis. Parasitology 121 (Suppl): S133–S146. [Google Scholar]
  9. Ottesen EA, Ismail MM, Horton J, 1999. The role of albendazole in programs to eliminate lymphatic filariasis. Parasitol Today 15 : 382–386. [Google Scholar]
  10. Bockarie MJ, Tisch DJ, Kastens W, Alexander ND, Dimber Z, Bockarie F, Ibam E, Alpers MP, Kazura JW, 2002. Mass treatment to eliminate filariasis in Papua New Guinea. N Engl J Med 347 : 1841–1848. [Google Scholar]
  11. Boyd HA, Waller LA, Flanders WD, Beach MJ, Sivilus JS, Lovince R, Lammie PJ, Addiss DG, 2004. Community- and individual-level determinants of Wuchereria bancrofti infection in Leogane Commune, Haiti. Am J Trop Med Hyg 70 : 266–272. [Google Scholar]
  12. McLaughlin SI, Radday J, Michel MC, Addiss DG, Beach MJ, Lammie PJ, Lammie J, Rheingans R, Lafontant J, 2003. Frequency, severity and costs of adverse reactions following mass treatment for lymphatic filariasis using diethylcarbamazine and albendazole, Leogane, Haiti, 2000. Am J Trop Med Hyg 68 : 568–573. [Google Scholar]
  13. Mathieu E, Deming M, Lammie P, McLaughlin S, Beach M, Deodat DJ, Addiss D, 2003. Comparison of methods for estimating drug coverage for filariasis elimination, Leogane, Haiti. Trans R Soc Trop Med Hyg 97 : 501–505. [Google Scholar]
  14. Mathieu E, Lammie PJ, Radday J, Montilus W, Beach MJ, Streit T, Wendt J, Addiss DG, 2004. What influenced people to participate in a mass treatment campaign against lymphatic filariasis? Ann Trop Med Parasitol 98 : 703–714. [Google Scholar]
  15. Beau de Rochars M, Direny AN, Roberts JM, Addiss DG, Radday J, Beach MJ, Streit TG, Dardith D, Lafontant J, Lammie PJ, 2004. Community-wide reduction in prevalence and intensity of intestinal helminths as a collateral benefit of lymphatic filariasis elimination programs. Am J Trop Med Hyg 71 : 466–470. [Google Scholar]
  16. Stolk W, Swaminathan S, van Oortmarssen GJ, Das PK, Habbema JD, 2003. Prospects for elimination of Bancroftian filariasis by mass drug treatment in Pondicherry, India: a simulation study. J Infect Dis 188 : 1371–1381. [Google Scholar]
  17. Washington CH, Radday J, Streit TG, Boyd HA, Beach MJ, Addiss DG, Lovince R, Lovegrove M, Lafontant JG, Lammie PJ, Hightower AW, 2004. Spatial clustering of filarial transmission before and after a mass drug administration in a setting of low infection prevalence. Filaria J 3 : 3. [Google Scholar]
  18. WHO, 2000. Preparing and Implementing a National Plan to Eliminate Lymphatic Gilariasis. Geneva: World Health Organization.
  19. Krishnamoorthy K, Ramu K, Srividya A, Appavoo NC, Saxena NB, Lal S, Das PK, 2000. Cost of mass annual single dose diethylcarbamazine distribution for the large scale control of lymphatic filariasis. Ind J Med Res 111 : 81–89. [Google Scholar]
  20. Michael E, Meyrowitsch DW, Simonsen PE, 1996. Cost and cost effectiveness of mass diethylcarbamazine chemotherapy for the control of Bancroftian filariasis: comparison of four strategies in Tanzania. Trop Med Int Health 1 : 414–426. [Google Scholar]

Data & Media loading...

  • Received : 25 Apr 2005
  • Accepted : 29 Jun 2005

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error